Maxim analyst Jason McCarthy raised the firm's price target on Compass Pathways to $20 from $12 and keeps a Buy rating on the shares. Compass Pathways reported Q1 results with an operating loss of ($42.9M) and ended the period with $466M, the analyst tells investors in a research note. Compass's Commissioner's National Priority Voucher award should accelerate the company's commercial timelines, driving the firm's price target increase, the firm added.
